AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure

Zacks Investment Research News Agency

Yesterday•Zacks Investment Research

Stocks Medium Importance Neutral

AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure

Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.

Related Symbols 1

A AMGN AMGN

Source: Zacks Investment Research

Visit Source

0 0 0

Comment

Comments

No comments yet

Be the first person to comment on this news item.

Category Stocks

Source Zacks Investment Research

Published Yesterday

Likes 0

Comments 0

Shares 0

News ID #1,165

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.

AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure

Comments

User Menu